ClinicalTrials.gg
Enrolling by invitationNCT07153003Updated Mar 18, 2026

Efficacy And Safety Of Tramadol And Oxycodone Versus Oxycodone Monotherapy For Pain Control After Primary Total Knee And Total Hip Arthroplasty

A Phase 4 interventional study of Oxycodone and Tramadol and Oxycodone in Post Operative Pain, sponsored by Mayo Clinic. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-18.

Sponsored by Mayo Clinic · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
560
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies testing oxycodone in Pain, Postoperative — 5 open to participants now, 7 under way, 1 of them phase 3. Oxycodone · Pain, Postoperative.

Planned enrollment
2nd of 32
560 · median 126
Started
2026
with 2 others
Phase 4
18 of 32
2 open now
Registered
30th of 32
by date

Among the 32 studies testing oxycodone in Pain, Postoperative, this one is the 2nd largest by planned enrollment, is one of 3 that started in 2026, is one of 18 in phase 4, and was the 30th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

5 of the 32 studies testing oxycodone in Pain, Postoperative are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About oxycodone

Oxycodone: first FDA approval 1950 (PERCODAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing oxycodone in Pain, Postoperative, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effectiveness and safety of tramadol and oxycodone therapy in comparison to oxycodone alone as part of a multimodal pain regimen to reduce postoperative opioid consumption, pain, minimize adverse events and complications for primary total knee arthroplasty (TKA) and primary total hip arthroplasty (THA).

03

Conditions studied

  • Post Operative Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primary TKA
  • Primary THA
  • Age > 18 years

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years
  • Revision or partial TKA/THA
  • Pregnant or breast-feeding women
  • Simultaneous bilateral TKA/THA
  • Primary TKA/THA due to oncologic reason
  • Anaphylaxis to opioids
  • Renal or liver failure
  • Prior opioid use disorder/ substance use disorder
  • Opioid use within 3 months prior to surgery
  • Patients needing a translator and those with dementia or other cognitive deficits
  • Patients taking Monoamine Oxidase Inhibitor (MOAI) medications (phenelzine, tranylcypromine) or benzodiazepine medications (alprazolam, diazepam, lorazepam, etc)
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
560 participants (estimated)

Study arms

  • Active comparator
    Oxycodone Only

    Patient's will be prescribed only Oxycodone for post operative pain management.

    Drug: Oxycodone

  • Active comparator
    Multimodal Pain Control

    Patients will be prescribed Tramadol and Oxycodone for post operative opioid pain relief.

    Drug: Tramadol and Oxycodone

Interventions

  • Patients will receive oral Oxycodone only to treat post-operative pain: Oxycodone 5mg * Patients ≤75 years old: 5mg or 10 mg PO every 4 hr as needed * 5 mg for pain rated 4-6 * 10 mg for pain rated 7-10 * Patients \>75 years old and/or sensitive to opioids or sedatives: 2.5mg or 5mg every 4hr as needed * 2.5mg for pain rated 4-6 * 5mg for pain rated 7-10

  • DrugTramadol and Oxycodone

    Drug pages: TramadolStudies of TramadolTramadol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · OxycodoneStudies of OxycodoneOxycodone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will receive a combination of Tramadol and Oxycodone to take orally to treat post-operative pain: Tramadol 50mg * Patients ≤75 years old: 50 mg for pain rated 4-6; 100 mg for pain rated 7-10 * Patients \>75 years old and/or sensitive to opioids or sedatives; use 50 mg * Dosing is every 8 hours as needed. Cumulative dose not to exceed 400mg in 24 hours Oxycodone 5mg * Patients ≤75 years old: 5mg or 10 mg PO every 4 hr as needed if still having pain after maximum tramadol administration * 5 mg for pain rated 4-6 * 10 mg for pain rated 7-10 * Patients \>75 years old and/or sensitive to opioids or sedatives: 2.5mg or 5mg every 4 hr as needed if still having pain after maximum tramadol administration * 2.5 mg for pain rated 4-6 * 5 mg for pain rated 7-10

06

What researchers measure

Primary outcomes

  1. Cumulative opioid consumption during the first 30 days

    Total amount of opioid medication taken for the first 30 days following surgery, reported in milligrams (mg)

    Time frame: 30 days

Secondary outcomes

  1. Cumulative opioid consumption during the first 90 days

    Total amount of opioid medication taken for the first 90 days following surgery, reported in milligrams (mg)

    Time frame: 90 days

  2. Postoperative opioid refills within 90 days

    Total number of opioid medication refills within 90 days post surgery

    Time frame: 90 days

  3. Number of unused opioid pills

    Total number of unused opioid pills unused after 90 days

    Time frame: 90 days

  4. Change in Visual Analogue Scale (VAS) pain scores

    Pain values reported by participants will be assessed using the 100-mm Visual Analogue Scale (VAS). The VAS line will be 100 mm long with no intermediate delineations. Each end will be marked with "no pain" on the left, and "worst possible pain" on the right. Participants will identify their pain level by indicating a point on the line between each end. That point will be measured from the "No pain" end, and the number of millimeters will be reported as the pain score.

    Time frame: Daily for 90 days

  5. Number of complications

    Total number of complications experienced post-operatively, complications include stiffness, VTE, GI hemorrhage, falls, ileus, dizziness, changes in vision, and miosis.

    Time frame: 90 days

  6. Number of emesis episodes

    Postoperative nausea and vomiting will be measured by total number of emesis episodes

    Time frame: 90 days

  7. Rate of antiemetic use

    Total number of times patients require use of antiemetics for nausea or vomiting

    Time frame: 90 days

  8. Satisfaction survey scores

    Patients will be provided with a satisfaction survey 90 days post-surgery. The survey consists of 2 questions rated on a Likert scale measuring understanding and confidence in medication use, and one yes/no question. The Likert scale questions are ranked from "0" - no understanding/low confidence to "10" - full understanding/high confidence. Higher scores indicate greater satisfaction with the prescribed opioid therapy plan.

    Time frame: 90 days

  9. Length of Stay

    Total number of days patients stay inpatient

    Time frame: Post-operatively, up to 90 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Sep 2030, 54 months after the start.

Of 535 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's planned 54 months is above that.

Counting every sponsor, half of 545 studies reached it within 16 months; a quarter within 8 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2025
First posted
Sep 3, 2025
StartActual
Feb 2, 2026
Primary completionEst.
Sep 1, 2030
CompletionEst.
Sep 1, 2031
Last update
Mar 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07153003
Lead sponsor
Mayo Clinic
Responsible party
Charles P. Hannon (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Sep 3, 2025
Start date
Feb 2, 2026
Primary completion
Sep 1, 2030 (estimated)
Completion
Sep 1, 2031 (estimated)
Last update
Mar 18, 2026

Study contacts

Charles P. Hannon, MD, MBA
principal investigator · Mayo Clinic

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oxycodone

Start the discussion